Inhibition of c-Jun N-terminal kinase increases apoE expression in vitro and in vivo

Biochemical and Biophysical Research Communications

Volumn 387, Issue 3, 2009, Pages 516-520

  Pocivavsek, Ana ^a   Rebeck, G William ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ABCA1; Alzheimer's disease; Apolipoprotein E; Astrocytes; Cholesterol; Glia; Inflammation; JNK; Lipopolysaccharide; Signal transduction

Indexed keywords

APOLIPOPROTEIN E; JANUS KINASE; STRESS ACTIVATED PROTEIN KINASE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GLIA CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALZHEIMER DISEASE; ANIMALS; APOLIPOPROTEINS E; CELLS, CULTURED; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MICE; MICE, INBRED STRAINS; NEUROGLIA; PROTEIN KINASE INHIBITORS;

MUS;

EID: 68249093378     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.07.048     Document Type: Article

References (30)

1. Weisgraber K.H. Apolipoprotein E: structure-function relationships. Adv. Protein Chem. 45 (1994) 249-302
2. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., and Roses A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 90 (1993) 1977-1981
3. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81 (2001) 741-766
4. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
5. Laskowitz D.T., Thekdi A.D., Thekdi S.D., Han S.K., Myers J.K., Pizzo S.V., and Bennett E.R. Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. Exp. Neurol. 167 (2001) 74-85
6. Lynch J.R., Morgan D., Mance J., Matthew W.D., and Laskowitz D.T. Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response. J. Neuroimmunol. 114 (2001) 107-113
7. Lynch J.R., Tang W., Wang H., Vitek M.P., Bennett E.R., Sullivan P.M., Warner D.S., and Laskowitz D.T. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J. Biol. Chem. 278 (2003) 48529-48533
8. Pocivavsek A., Burns M.P., and Rebeck G.W. Low-density lipoprotein receptors regulate microglial inflammation through c-Jun N-terminal kinase. Glia 57 (2009) 444-453
9. Vitek M.P., Brown C.M., and Colton C.A. APOE genotype-specific differences in the innate immune response. Neurobiol. Aging (2007)
10. Grehan S., Tse E., and Taylor J.M. Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain. J. Neurosci. 21 (2001) 812-822
11. Pitas R.E., Boyles J.K., Lee S.H., Foss D., and Mahley R.W. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim. Biophys. Acta 917 (1987) 148-161
12. Uchihara T., Duyckaerts C., He Y., Kobayashi K., Seilhean D., Amouyel P., and Hauw J.J. ApoE immunoreactivity and microglial cells in Alzheimer's disease brain. Neurosci. Lett. 195 (1995) 5-8
13. Poirier J., Hess M., May P.C., and Finch C.E. Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning. Brain Res. Mol. Brain Res. 11 (1991) 97-106
14. Gafencu A.V., Robciuc M.R., Fuior E., Zannis V.I., Kardassis D., and Simionescu M. Inflammatory signaling pathways regulating ApoE gene expression in macrophages. J. Biol. Chem. 282 (2007) 21776-21785
15. Saura J., Petegnief V., Wu X., Liang Y., and Paul S.M. Microglial apolipoprotein E and astroglial apolipoprotein J expression in vitro: opposite effects of lipopolysaccharide. J. Neurochem. 85 (2003) 1455-1467
16. Boyles J.K., Pitas R.E., Wilson E., Mahley R.W., and Taylor J.M. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J. Clin. Invest. 76 (1985) 1501-1513
17. Murakami M., Ushio Y., Morino Y., Ohta T., and Matsukado Y. Immunohistochemical localization of apolipoprotein E in human glial neoplasms. J. Clin. Invest. 82 (1988) 177-188
18. Oram J.F., and Heinecke J.W. ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol. Rev. 85 (2005) 1343-1372
19. Hidding U., Mielke K., Waetzig V., Brecht S., Hanisch U., Behrens A., Wagner E., and Herdegen T. The c-Jun N-terminal kinases in cerebral microglia: immunological functions in the brain. Biochem. Pharmacol. 64 (2002) 781-788
20. Ip Y.T., and Davis R.J. Signal transduction by the c-Jun N-terminal kinase (JNK)-from inflammation to development. Curr. Opin. Cell Biol. 10 (1998) 205-219
21. Drosatos K., Sanoudou D., Kypreos K.E., Kardassis D., and Zannis V.I. A dominant negative form of the transcription factor c-Jun affects genes that have opposing effects on lipid homeostasis in mice. J. Biol. Chem. 282 (2007) 19556-19564
22. Dong L.M., and Weisgraber K.H. Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J. Biol. Chem. 271 (1996) 19053-19057
23. Hatters D.M., Peters-Libeu C.A., and Weisgraber K.H. Apolipoprotein E structure: insights into function. Trends Biochem. Sci. 31 (2006) 445-454
24. Riddell D.R., Zhou H., Atchison K., Warwick H.K., Atkinson P.J., Jefferson J., Xu L., Aschmies S., Kirksey Y., Hu Y., Wagner E., Parratt A., Xu J., Li Z., Zaleska M.M., Jacobsen J.S., Pangalos M.N., and Reinhart P.H. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J. Neurosci. 28 (2008) 11445-11453
25. Bales K.R., Liu F., Wu S., Lin S., Koger D., DeLong C., Hansen J.C., Sullivan P.M., and Paul S.M. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J. Neurosci. 29 (2009) 6771-6779
26. Manning A.M., and Davis R.J. Targeting JNK for therapeutic benefit: from junk to gold?. Nat. Rev. Drug Discov. 2 (2003) 554-565
27. Bogoyevitch M.A., and Arthur P.G. Inhibitors of c-Jun N-terminal kinases: JuNK no more?. Biochim. Biophys. Acta 1784 (2008) 76-93
28. Morishima Y., Gotoh Y., Zieg J., Barrett T., Takano H., Flavell R., Davis R.J., Shirasaki Y., and Greenberg M.E. Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J. Neurosci. 21 (2001) 7551-7560
29. Crocker S.J., Lamba W.R., Smith P.D., Callaghan S.M., Slack R.S., Anisman H., and Park D.S. c-Jun mediates axotomy-induced dopamine neuron death in vivo. Proc. Natl. Acad. Sci. USA 98 (2001) 13385-13390
30. Kuan C.Y., Whitmarsh A.J., Yang D.D., Liao G., Schloemer A.J., Dong C., Bao J., Banasiak K.J., Haddad G.G., Flavell R.A., Davis R.J., and Rakic P. A critical role of neural-specific JNK3 for ischemic apoptosis. Proc. Natl. Acad. Sci. USA 100 (2003) 15184-15189